The study identifies 15 non-toxic metabolic targets in M. tuberculosis for structure-based drug discovery, including several genes involved in essential metabolic pathways. Computational and experimental methods were used to evaluate potential inhibitors, resulting in the identification of 20 lead compounds, some of which are FDA-approved drugs.